These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

284 related items for PubMed ID: 17239554

  • 21. Predictive value of HIV-1 protease genotype and virtual phenotype on the virological response to lopinavir/ritonavir-containing salvage regimens.
    Loutfy MR, Raboud JM, Walmsley SL, Saskin R, Montaner JS, Hogg RS, Thompson CA, Harrigan PR.
    Antivir Ther; 2004 Aug; 9(4):595-602. PubMed ID: 15456091
    [Abstract] [Full Text] [Related]

  • 22. A randomized comparison of second-line lopinavir/ritonavir monotherapy versus tenofovir/lamivudine/lopinavir/ritonavir in patients failing NNRTI regimens: the HIV STAR study.
    Bunupuradah T, Chetchotisakd P, Ananworanich J, Munsakul W, Jirajariyavej S, Kantipong P, Prasithsirikul W, Sungkanuparph S, Bowonwatanuwong C, Klinbuayaem V, Kerr SJ, Sophonphan J, Bhakeecheep S, Hirschel B, Ruxrungtham K, HIV STAR Study Group.
    Antivir Ther; 2012 Aug; 17(7):1351-61. PubMed ID: 23075703
    [Abstract] [Full Text] [Related]

  • 23. Efficacy and safety of once-daily darunavir/ritonavir versus lopinavir/ritonavir in treatment-naive HIV-1-infected patients at week 48.
    Ortiz R, Dejesus E, Khanlou H, Voronin E, van Lunzen J, Andrade-Villanueva J, Fourie J, De Meyer S, De Pauw M, Lefebvre E, Vangeneugden T, Spinosa-Guzman S.
    AIDS; 2008 Jul 31; 22(12):1389-97. PubMed ID: 18614861
    [Abstract] [Full Text] [Related]

  • 24. Long-term safety and effectiveness of lopinavir/ritonavir in antiretroviral-experienced HIV-1-infected children.
    Rudin C, Wolbers M, Nadal D, Rickenbach M, Bucher HC, Pediatric Infectious Disease Group of Switzerland (PIGS), Swiss Mother and Child HIV Cohort Study (MoCHiV).
    Arch Dis Child; 2010 Jun 31; 95(6):478-81. PubMed ID: 20501542
    [Abstract] [Full Text] [Related]

  • 25. Long-term safety and effectiveness of ritonavir, nelfinavir, and lopinavir/ritonavir in antiretroviral-experienced HIV-infected children.
    Rudin C, Burri M, Shen Y, Rode R, Nadal D, Pediatric Infectious Disease Group of Switzerland, Swiss Mother and Child HIV Cohort Study (MoCHiV).
    Pediatr Infect Dis J; 2008 May 31; 27(5):431-7. PubMed ID: 18382386
    [Abstract] [Full Text] [Related]

  • 26. Lopinavir/ritonavir monotherapy or plus zidovudine and lamivudine in antiretroviral-naive HIV-infected patients.
    Delfraissy JF, Flandre P, Delaugerre C, Ghosn J, Horban A, Girard PM, Norton M, Rouzioux C, Taburet AM, Cohen-Codar I, Van PN, Chauvin JP.
    AIDS; 2008 Jan 30; 22(3):385-93. PubMed ID: 18195565
    [Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29. Characterization of virologic failure patients on darunavir/ritonavir in treatment-experienced patients.
    De Meyer S, Lathouwers E, Dierynck I, De Paepe E, Van Baelen B, Vangeneugden T, Spinosa-Guzman S, Lefebvre E, Picchio G, de Béthune MP.
    AIDS; 2009 Sep 10; 23(14):1829-40. PubMed ID: 19474650
    [Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. Prediction of early and confirmed virological response by genotypic inhibitory quotients for lopinavir in patients naïve for lopinavir with limited exposure to previous protease inhibitors.
    Torti C, Uccelli MC, Quiros-Roldan E, Gargiulo F, Tirelli V, Lapadula G, Regazzi M, Pierotti P, Tinelli C, De Luca A, Patroni A, Manca N, Carosi G.
    J Clin Virol; 2006 Apr 10; 35(4):414-9. PubMed ID: 16280255
    [Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34. Virological and pharmacological parameters predicting the response to lopinavir-ritonavir in heavily protease inhibitor-experienced patients.
    Marcelin AG, Cohen-Codar I, King MS, Colson P, Guillevic E, Descamps D, Lamotte C, Schneider V, Ritter J, Segondy M, Peigue-Lafeuille H, Morand-Joubert L, Schmuck A, Ruffault A, Palmer P, Chaix ML, Mackiewicz V, Brodard V, Izopet J, Cottalorda J, Kohli E, Chauvin JP, Kempf DJ, Peytavin G, Calvez V.
    Antimicrob Agents Chemother; 2005 May 10; 49(5):1720-6. PubMed ID: 15855487
    [Abstract] [Full Text] [Related]

  • 35. Virological characterization of patients failing darunavir/ritonavir or lopinavir/ritonavir treatment in the ARTEMIS study: 96-week analysis.
    Lathouwers E, De Meyer S, Dierynck I, Van de Casteele T, Lavreys L, de Béthune MP, Picchio G.
    Antivir Ther; 2011 May 10; 16(1):99-108. PubMed ID: 21311113
    [Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. Virological responses to atazanavir-ritonavir-based regimens: resistance-substitutions score and pharmacokinetic parameters (Reyaphar study).
    Pellegrin I, Breilh D, Ragnaud JM, Boucher S, Neau D, Fleury H, Schrive MH, Saux MC, Pellegrin JL, Lazaro E, Vray M.
    Antivir Ther; 2006 May 10; 11(4):421-9. PubMed ID: 16856615
    [Abstract] [Full Text] [Related]

  • 38. Predictive factors for response to a boosted dual HIV-protease inhibitor therapy with saquinavir and lopinavir in extensively pre-treated patients.
    von Hentig N, Babacan E, Staszewski S, Stürmer M, Doerr HW, Lötsch J.
    Antivir Ther; 2007 May 10; 12(8):1237-46. PubMed ID: 18240863
    [Abstract] [Full Text] [Related]

  • 39. A randomized trial to evaluate lopinavir/ritonavir versus saquinavir/ritonavir in HIV-1-infected patients: the MaxCmin2 trial.
    Dragsted UB, Gerstoft J, Youle M, Fox Z, Losso M, Benetucci J, Jayaweera DT, Rieger A, Bruun JN, Castagna A, Gazzard B, Walmsley S, Hill A, Lundgren JD, MaxCmin2 Trial Group.
    Antivir Ther; 2005 May 10; 10(6):735-43. PubMed ID: 16218173
    [Abstract] [Full Text] [Related]

  • 40. Genotypic resistance analysis of the virological response to fosamprenavir-ritonavir in protease inhibitor-experienced patients in CONTEXT and TRIAD clinical trials.
    Marcelin AG, Flandre P, Molina JM, Katlama C, Yeni P, Raffi F, Antoun Z, Ait-Khaled M, Calvez V.
    Antimicrob Agents Chemother; 2008 Dec 10; 52(12):4251-7. PubMed ID: 18852278
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 15.